Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873785 | 0.90 | HRH4 (0.54) | HRH4NR1H2NR1H3HRH2HRH1 | |
| SCHEMBL15727044 | 0.80 | HRH4 (0.42) | HRH4NR1H2NR1H3HRH2HRH1 | |
| SCHEMBL4877657 | 0.80 | UCHL1 (0.42) | HRH4NR1H2NR1H3HRH2HRH1 | |
| SCHEMBL4877858 | 0.77 | UCHL1 (0.37) | HRH4NR1H2NR1H3PIK3R1PIK3CA | |
| SCHEMBL4875239 | 0.77 | EED (0.38) | NR1H2NR1H3PIK3R1PIK3CARET | |
| SCHEMBL16994028 | 0.75 | HTT (0.47) | NR1H2NR1H3BRD3HRH2RET | |
| SCHEMBL605075 | 0.74 | HRH4 (0.65) | HRH4NPY5RHRH2HRH1HRH3 | |
| SCHEMBL604878 | 0.73 | HRH4 (0.74) | HRH4HRH2HRH1HRH3 | |
| SCHEMBL604300 | 0.72 | HRH4 (0.75) | HRH4HRH3 | |
| SCHEMBL604301 | 0.72 | HRH4 (0.75) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | HRH4 3013/4885NR1H2 2355/4885NR1H3 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.